Effect of light/dark regimen on N-nitrosoethylurea-induced transplacental carcinogenesis in rats.
Pregnant females were randomly subdivided into three groups (24 rats per group) and kept at the 12:12 h light/dark regimen (group 1), at the constant light illumination (24 h a day, group 2) or at the continuous darkness (group 3). N-nitrosoethylurea (NEU) has been injected into the tail vein of all rats (80 mg/kg) on the 18-19th day of the pregnancy. After the delivery the lacting dams and their progeny during the lactation period (1 month after delivery) were kept also at the three different light/dark regimens. Then all offspring from each group was kept at the 12:12 h light/dark regimen, males and females separately, and were observed until natural death. The exposure to constant light significantly promoted the transplacental carcinogenesis whereas the exposure to constant darkness inhibited it. The incidence of total tumors, tumors of both a peripheral nervous system and kidney was 2.6; 2.5 and 8.5 times higher, and survival significantly shorter, correspondingly, in rats from the group 2 exposed to the constant light regimen as compared to the group 1 (12:12 h light/dark regimen) (P<0.05). On the other hand, the exposure to the continuous darkness during the pregnancy and the lactation period significantly inhibited the transplacental carcinogenesis in the offspring of rats treated with NEU. The incidence of total tumors, tumors of a peripheral nervous system was by 2.4 and 2.7 times less, and survival longer, respectively, in exposed to the darkness rats from the group 3 as compared to the group 1 (12:12 h light/dark regimen) (P<0.05). Thus, our data firstly have shown the modifying effect of light-dark regimen on the realization of the transplacental carcinogenesis induced by NEU in rats.
Beniashvili
D S
DS
Department of Pathology, G. Wolfson Medical Center, Holon, Israel.
Benjamin
S
S
Baturin
D A
DA
Anisimov
V N
VN
D000477:Alkylating Agents / Q000494:pharmacology*; D000818:Animals; D003624:Darkness; D004307:Dose-Response Relationship, Radiation; D005038:Ethylnitrosourea / Q000494:pharmacology*; D005260:Female; D007680:Kidney Neoplasms / Q000209:etiology; D008027:Light / Q000009:adverse effects; D008297:Male; D009374:Neoplasms, Experimental / Q000209:etiology* / Q000401:mortality; D009423:Nervous System Neoplasms / Q000209:etiology; D017933:Peripheral Nervous System / Q000187:drug effects / Q000473:pathology / Q000528:radiation effects; D017440:Photoperiod; D010920:Placenta / Q000187:drug effects / Q000473:pathology / Q000528:radiation effects*; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects; D051381:Rats; D017208:Rats, Wistar; D016019:Survival Analysis; D015996:Survival Rate
D000477:Alkylating Agents; D005038:Ethylnitrosourea